British Patient Capital, the venture capital arm of the UK government’s British Business Bank, has made a significant investment in Myricx Bio, a London-based life sciences company.
This undisclosed amount is part of a £90 million Series A funding round aimed at advancing Myricx Bio’s innovative cancer drug technology. The investment was facilitated through the £425 million Future Fund: Breakthrough program.
Co-led by prominent life sciences investors Novo Holdings and Abingworth, the funding round also saw participation from new investors Cancer Research Horizons and Eli Lilly and Company, alongside initial investors Brandon Capital and Sofinnova Partners.
Myricx Bio, a spin-out from Imperial College London and the Francis Crick Institute, specializes in developing technology that targets cancer cells with minimal side effects compared to conventional treatments. Their approach focuses on inhibiting an enzyme called NMT, crucial for cancer cell survival and proliferation.
The funds raised will support further development of Myricx Bio’s technology, with the goal of offering novel treatment options for oncology patients with significant unmet needs.
Ian Connatty, managing director of direct and co-investment at British Patient Capital, praised Myricx Bio’s promising pre-clinical data and its potential to make strides in the oncology sector. He emphasized the company’s commitment to advancing new therapies for cancer patients.
Carmine Circelli, director of life sciences at British Patient Capital, highlighted the broad applicability of Myricx Bio’s approach across diverse patient populations, including those resistant to current therapies.
Dr. Robin Carr, CEO of Myricx Bio, expressed gratitude for the support from new investors and underscored the company’s readiness to expand its research and development capabilities with the newly acquired resources.
This investment marks another milestone in British Patient Capital’s strategy to bolster the UK’s biotech sector, following a recent £10 million investment in Curve Therapeutics for cancer drug discovery technology.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
British Patient Capital, the venture capital arm of the UK government’s British Business Bank, has made a significant investment in Myricx Bio, a London-based life sciences company.
This undisclosed amount is part of a £90 million Series A funding round aimed at advancing Myricx Bio’s innovative cancer drug technology. The investment was facilitated through the £425 million Future Fund: Breakthrough program.
Co-led by prominent life sciences investors Novo Holdings and Abingworth, the funding round also saw participation from new investors Cancer Research Horizons and Eli Lilly and Company, alongside initial investors Brandon Capital and Sofinnova Partners.
Myricx Bio, a spin-out from Imperial College London and the Francis Crick Institute, specializes in developing technology that targets cancer cells with minimal side effects compared to conventional treatments. Their approach focuses on inhibiting an enzyme called NMT, crucial for cancer cell survival and proliferation.
The funds raised will support further development of Myricx Bio’s technology, with the goal of offering novel treatment options for oncology patients with significant unmet needs.
Ian Connatty, managing director of direct and co-investment at British Patient Capital, praised Myricx Bio’s promising pre-clinical data and its potential to make strides in the oncology sector. He emphasized the company’s commitment to advancing new therapies for cancer patients.
Carmine Circelli, director of life sciences at British Patient Capital, highlighted the broad applicability of Myricx Bio’s approach across diverse patient populations, including those resistant to current therapies.
Dr. Robin Carr, CEO of Myricx Bio, expressed gratitude for the support from new investors and underscored the company’s readiness to expand its research and development capabilities with the newly acquired resources.
This investment marks another milestone in British Patient Capital’s strategy to bolster the UK’s biotech sector, following a recent £10 million investment in Curve Therapeutics for cancer drug discovery technology.
